Oruka Therapeutics (ORKA) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications.

• Focuses on antibody engineering and format innovations to improve efficacy and dosing regimens of standard-of-care medicines.

• Lead programs target interleukin-23 (ORKA-001) and interleukin-17A/F (ORKA-002) for multiple chronic skin and inflammatory diseases.

• Aims to set new treatment standards in large markets with unmet needs by leveraging proven mechanisms and half-life extension technology.

Financial performance and metrics

• As of December 31, 2025, 48,722,309 shares of common stock and 137,138 shares of Series B Preferred Stock were outstanding.

• Common stock last reported sale price was $50.43 per share on April 1, 2026.

Use of proceeds and capital allocation

• Intended use of net proceeds from securities sales will be detailed in the applicable prospectus supplement; management retains broad discretion over allocation.